OncoC4
OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026
33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with…